Diffusion MRI in Heart Failure

Conditions:Cardiology, Cardiology, Orthopedic
Therapuetic Areas:Cardiology / Vascular Diseases, Orthopedics / Podiatry
Age Range:18 - 85
Start Date:June 30, 2017
End Date:December 2020
Contact:David E. Sosnovik, MD

Use our guide to learn which trials are right for you!

The development of symptomatic heart failure is frequently preceded by a pre-clinical period
of structural remodeling in the heart. The remodeling process driving this transition,
however, remains poorly understood. The investigators hypothesize that imaging the diffusion
of water in the heart with MRI will allow its microstructure to be resolved. The
investigators further hypothesize that the characterization of microstructural changes in the
heart will help elucidate the pathogenesis of heart failure and the transition from a
compensated to a decompensated state. Patients with recent myocardial infarcts and left
ventricular hypertrophy, who are at risk for the development of heart failure, will be
enrolled. The participants will undergo serial diffusion tensor MRI (DTI) imaging of the
heart to characterize changes in myocardial microstructure over time.

Inclusion Criteria:

- Healthy adults with no history of hypertension, diabetes or heart disease

- Patients with ST Elevation MI within last 6-10 weeks who are angina free, and have
been seen by a cardiologist since discharge

- Patients with episode of heart failure within last 12 months and left ventricular
hypertrophy, documented by echocardiogram or MRI.

Exclusion Criteria:

1. Presence of metallic foreign bodies/objects

2. Selected medical devices and implants

3. Pacemakers, implantable defibrillators, life vests

4. Coronary artery stent within last 6 weeks (unless the stent is a MRI-inert
chromium-cobalt stent)

5. Known untreated ventricular arrhythmia such as sustained ventricular tachycardia
within last 12 months

6. Atrial fibrillation that is not well rate controlled (heart rate >125)

7. Unstable angina within last 2 months that has not been fully evaluated by a

8. Syncope within last 6 weeks

9. Hemodynamic instability (Systolic BP less than 100 or greater than 180)

10. Decompensated heart failure (inability to lie flat and perform a breath-hold).

11. Glomerular filtration rate (GFR) < 60 for those receiving gadolinium.

12. Labile GFR that is not stable/similar on last 2 measurements (for those receiving

13. Patients with GFR < 20 or on any form of dialysis.

14. Infiltrative cardiomyopathy (amyloid, sarcoid, hemachromatosis)

15. Recent surgery (within the last 3 months)

16. Prior stroke with large residual deficit

17. Presence of liver or respiratory failure

18. Pregnancy and nursing mothers

19. Claustrophobia

20. Known seizure disorder
We found this trial at
Charlestown, Massachusetts 02129
Charlestown, MA
Click here to add this to my saved trials